Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture

The Osteoporosis Clinic, Aarhus Amtssygehus, Aarhus University Hospital, Tage Hansens Gade 2, DK-8000, Aarhus C, Denmark.
Calcified Tissue International (Impact Factor: 3.27). 09/2006; 79(2):76-83. DOI: 10.1007/s00223-006-0021-7
Source: PubMed


We studied the effect of proton pump inhibitors, histamine H(2) receptor antagonists, and other types of antacid drugs on fracture risk. All cases were subjects with any fracture sustained during the year 2000 (n = 124,655). For each case, three controls (n = 373,962) matched on age and gender were randomly drawn from the background population. The primary exposure variables were use of proton pump inhibitors, histamine H(2) antagonists, and other antacid drugs. Adjustments were made for several confounders, including diagnosis of an ulcer, nonsteroidal anti-inflammatory drug use, use of histamine H(1) antagonists, stomach resection, previous fracture, and use of corticosteroids. The effect of dose was examined by stratifying for cumulated dose (defined daily dose). Use of proton pump inhibitors was associated with an increase in fracture risk for use within the last year [odds ratio (OR) = 1.18, 95% confidence interval (CI) 1.12-1.43 for overall fracture risk; OR = 1.45, 95% CI 1.28-1.65 for hip fractures; and OR = 1.60, 95% CI 1.25-2.04 for spine fractures). Histamine H(2) antagonists were associated with a decreased fracture risk if they had been used within the last year (OR = 0.88, 95% CI 0.82-0.95 for any fracture, OR = 0.69, 95% CI 0.57-0.84 for hip fractures). Other antacids were not associated with overall fracture risk but were associated with hip and spine fractures. Proton pump inhibitors appeared to be associated with a limited increase in fracture risk, in contrast to histamine H( 2 ) antagonists, which seemed to be associated with a small decrease in fracture risk. In all cases, the changes in risk estimates were small and the clinical significance was limited.


Available from: Peter Vestergaard
  • Source
    • "PPIs have been widely used since their introduction in the late 1980s. Several large observational studies suggest that PPI use is associated with a modest increase in osteoporotic fracture risk [Yang et al. 2006; Yu et al. 2008; Vestergaard et al. 2006b; Targownik et al. 2008]. Based on these and two other studies, the US Food and Drug Administration revised labeling for PPIs in May 2010 to include information about the potential risk of hip, spinal, or radial fractures. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug-induced osteoporosis is a significant health problem and many physicians are unaware that many commonly prescribed medications contribute to significant bone loss and fractures. In addition to glucocorticoids, proton pump inhibitors, selective serotonin receptor inhibitors, thiazolidinediones, anticonvulsants, medroxyprogesterone acetate, aromatase inhibitors, androgen deprivation therapy, heparin, calcineurin inhibitors, and some chemotherapies have deleterious effects on bone health. Furthermore, many patients are treated with combinations of these medications, possibly compounding the harmful effects of these drugs. Increasing physician awareness of these side effects will allow for monitoring of bone health and therapeutic interventions to prevent or treat drug-induced osteoporosis.
    Therapeutic advances in musculoskeletal disease 10/2014; 6(5):185-202. DOI:10.1177/1759720X14546350
  • Source
    • "Little is known on the effects of drugs affecting histamine signaling on the skeletal system in humans. The data on the effects of H 2 antagonists are conflicting [4] [5] [8] [18] [20] [43], and, to our knowledge, only one population-based study and one clinical study addressed the effect of H 1 antagonists on bone mineral density or content [18] [41]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Histamine receptors are expressed on bone cells and histamine may be involved in regulation of bone metabolism. The aim of the present study was to investigate the effects of loratadine (an H1 receptor antagonist), ranitidine (an H2 receptor antagonist) and betahistine (an H3 receptor antagonist and H1 receptor agonist) on bone mechanical properties in rats. Loratadine (5mg/kg/day, po), ranitidine (50mg/kg/day, po), or betahistine dihydrochloride (5mg/kg/day, po), were administered for 4 weeks to non-ovariectomized and bilaterally ovariectomized (estrogen-deficient) 3-month-old rats, and their effects were compared with appropriate controls. Serum levels of bone turnover markers, bone mineralization and mechanical properties of the proximal tibial metaphysis, femoral diaphysis and femoral neck were studied. In rats with normal estrogen level, administration of loratadine slightly favorably affected mechanical properties of compact bone, significantly increasing the strength of the femoral neck (p<0.05), and tending to increase the strength of the femoral diaphysis. Ranitidine did not significantly affect the investigated parameters, and betahistine decreased the strength of the tibial metaphysis (cancellous bone, p<0.01). There were no significant effects of the drugs on serum bone turnover markers. In estrogen-deficient rats, the drugs did not significantly affect the investigated skeletal parameters. In conclusion, the effects of histamine H1, H2 and H3 receptor antagonists on the skeletal system in rats were differential and dependent on estrogen status.
    Pharmacological reports: PR 02/2014; 66(1):93-99. DOI:10.1016/j.pharep.2013.08.010 · 1.93 Impact Factor
  • Source
    • "Calcium solubilization is thought to be prerequisite for calcium absorption in the small intestine, with the stomach's acidic environment inducing the dissolution of calcium salts and the release of ionized calcium (Bo-Linn et al. 1984; Sipponen and Harkonen 2010). To this end, several clinical studies reported a positive association between the long-term use of acid suppressing agents and bone fractures (Vestergaard et al. 2006; Yang et al. 2006; Ito and Jensen 2010). Moreover, short and long-term use of acid suppressing agents decreased BMD (Adachi et al. 1998; Kinjo et al. 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We have recently demonstrated that mice with disruption of claudin-18 (Cldn-18) gene exhibited osteopenia due to increased bone resorption (BR). In this study, we found that gastric pH was significantly higher in Cldn-18 knockout (KO) mice compared to heterozygous control mice at 10 weeks of age. To test the possibility that the increased BR in the Cldn-18 KO mice fed a normal-Ca diet is a consequence of decreased Ca absorption caused by increased stomach pH, we subjected KO and control mice to a normal-Ca and high-Ca diet at birth. Serum Ca levels were significantly lower in Cldn-18 KO mice compared to control mice at a normal-Ca diet but not at high-Ca diet. Dual energy X-ray absorptiometry revealed that a high-Ca diet significantly increased lumbar bone mineral density (BMD), but had no effect on femur/tibia BMD in both Cldn-18 KO and control mice compared to a normal-Ca diet. While a high-Ca diet did not affect volumetric BMD, trabecular, and cortical parameters of the lumbar vertebra (LV) as measured by μCT, the size of the LV did increase, in both genotypes due to reduced BR. Comparison of the skeletal phenotype of high-Ca Cldn-18 KO and control mice revealed that an osteopenia phenotype seen at a normal-Ca diet was still maintained at different skeletal sites in the KO mice till 10 weeks of age. In conclusion, our findings suggest that increased BR is likely caused by direct effects of a lack of Cldn-18 on osteoclasts rather than gastric pH changes.
    01/2014; 2(1):e00200. DOI:10.1002/phy2.200
Show more